Objective To compare the rate of moderate to severe exacerbations between triple therapy
and dual therapy or monotherapy in patients with chronic obstructive pulmonary disease …

Background Guidelines recommend that treatment with a long-acting β 2 agonist (LABA), a
long-acting muscarinic antagonist (LAMA), and inhaled corticosteroids (ICS), ie triple …

Background This study aims to compare the effects of single inhaler triple therapy comprised
of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting …

Purpose Role of triple therapy in chronic obstructive pulmonary disease (COPD)
management is supported by growing evidence, but consensus is lacking on various …

Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …

We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …

Recently, two “fixed triple” single-inhaler combinations of an inhaled corticosteroid (ICS), a
long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have …

Rationale: There is uncertainty on the use of using triple therapy (inhaled
corticosteroids/long-acting β-agonist/long-acting muscarinic antagonist) inhaler therapy for …

Triple inhaled therapy for chronic obstructive pulmonary disease (COPD) consists of an
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …

Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic
obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared …